Video

Dr. Udit Verma on Regorafenib in Patients With mCRC

Author(s):

Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer.

Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

In the phase IIIB CONSIGN study, 2872 patients with mCRC who failed standard therapy were treated with regorafenib, which demonstrated a median progression-free survival of 2.7 months. This retrospective subgroup analysis sought to confirm previous findings as well as the safety profile of regorafenib. This study’s primary endpoint was safety, Verma adds.

The most common grade 3 adverse events were hand-foot skin reaction (16%), hypertension (15%), fatigue, and diarrhea. These findings were similar as to what was reported in the phase III CORRECT trial, Verma explains.

Related Videos
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Andrew Davis, MD
Noa Biran, MD